Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study
NCT06573853
Summary
The goal of this retrospective study is to compare the long-term follow-up outcomes of pulses field ablation (PFA) Vs. radiofrequency ablation (RFA) for the patients with paroxysmal supraventricular tachycardia (PSVT). The main question to answer is: Does the PFA was more effecient and safer that RFA for treatment of PSVT during procedure and after 1-year follow-up? Researchers will compare the acute and long-term efficiency and safety between PFA and RFA. 1. Recieved PFA or RFA 1 year ago 2. Finish the visit to the clinic at 1, 3, 6, 12 months for examinations and blood testings 3. Patients recieved PFA and PFA under propensity matched comparison according to differen variety of PSVT
Eligibility
Inclusion Criteria: 1. Patients with symptomatic PSVT including: atrioventricular nodal re-entrant tachycardia (AVNRT), atrioventricular re-entrant tachycardia (AVRT); 2. Age range: 18 years old ≤ age ≤ 80 years old, with no gender restriction; 3. Willing to receive the examinations and testings during one year follow-up required by the protocol; 4. Voluntary signed informed consent. Exclusion Criteria: 1. Organic heart disease; 2. History of cardiac surgery; 3. Previous failed ablation of PSVT; 4. Presence of any implants, such as a permanent pacemaker; 5. Patients with invasive systemic infections or advanced malignant tumors; 6. Contraindications for septal puncture or retrograde transaortic access surgery; 7. Any condition that makes the use of heparin or aspirin inappropriate; 8. Pregnant or lactating women; 9. Inability to fully comply with the study procedures and follow-ups or to provide their own informed consent; 10. Coexistence with other arrhythmias, such as atrial fibrillation.
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06573853